RxDoctor Payments Data

Jennifer Higdon

Nurse Practitioner · Louisville, KYNPI 1457707838

Payments from drug & device makers

$5,724in general payments, 2019–2025

Across 211 payments — averaging $27.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alnylam Pharmaceuticals Inc.$960
  • Johnson & Johnson$916
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$806
  • AbbVie$787
  • Phathom Pharmaceuticals, Inc.$734
  • E.r. Squibb & Sons, L.L.C.$215
  • plus $1K from 19 others

What the payments were for

  • Consulting fees$96017%
  • Speaking & faculty fees$5139%
  • Food & beverage$4,09171%
  • Education$1603%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,724 in reported general payments places this provider in the 90th percentile of 1,918 nurse practitioner providers in Kentucky.

See all nurse practitioner providers in Kentucky

Medicare billing

Part B allowed, 2024
$41,913
Medicare patients
325
Services billed
450

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase15$86,951
XifaxanRifaximin15$78,403
LinzessLinaclotide28$26,184
Mesalamine ErMesalamine15$6,856
Colestipol Hcl34$5,415
Dexlansoprazole DrDexlansoprazole11$5,184
Mesalamine17$4,473
Pantoprazole Sodium292$4,209
Esomeprazole Magnesium58$3,999
Balsalazide Disodium13$3,186
Sucralfate56$2,419
Omeprazole161$1,847
Dicyclomine Hcl76$1,812
Lansoprazole46$1,776
Ondansetron OdtOndansetron35$858

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$787$113,13443 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$806$78,40315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,918 nurse practitioner providers in Kentucky.

Other nurse practitioner in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →